Characteristics of the FHCRC study cohort (n = 3918)
| Characteristic . | No. (%) . |
|---|---|
| Recipient age at transplantation, years | |
| Median | 43 |
| Range | 0-78 |
| Diagnosis | |
| Acute leukemia | 1605 (41) |
| Chronic myeloid leukemia | 971 (25) |
| Myelodysplastic syndromes or myeloproliferative neoplasms | 638 (16) |
| Chronic lymphocytic leukemia | 110 (3) |
| Malignant lymphoma or multiple myeloma | 593 (15) |
| Histiocytic sarcoma | 1 |
| Donor-recipient gender combination | |
| Male to male | 1337 (34) |
| Male to female | 873 (22) |
| Female to male | 946 (24) |
| Female to female | 762 (19) |
| HLA and donor type | |
| HLA-matched related | 1819 (46) |
| Unrelated HLA-matched, confirmed by high-resolution typing | 1213 (31) |
| Unrelated HLA-matched, unconfirmed by high-resolution typing | 239 (6) |
| HLA-mismatched unrelated | 666 (17) |
| Graft source | |
| Bone marrow | 2179 (56) |
| Mobilized blood cells | 1739 (44) |
| Conditioning regimen | |
| Myeloablative with <1000 cGy total body irradiation | 1340 (34) |
| Myeloablative with ≥1000 cGy total body irradiation | 1887 (18) |
| Nonmyeloablative | 691 (18) |
| Prior grade 2-4 acute GVHD* | 2848 (73) |
| Characteristic . | No. (%) . |
|---|---|
| Recipient age at transplantation, years | |
| Median | 43 |
| Range | 0-78 |
| Diagnosis | |
| Acute leukemia | 1605 (41) |
| Chronic myeloid leukemia | 971 (25) |
| Myelodysplastic syndromes or myeloproliferative neoplasms | 638 (16) |
| Chronic lymphocytic leukemia | 110 (3) |
| Malignant lymphoma or multiple myeloma | 593 (15) |
| Histiocytic sarcoma | 1 |
| Donor-recipient gender combination | |
| Male to male | 1337 (34) |
| Male to female | 873 (22) |
| Female to male | 946 (24) |
| Female to female | 762 (19) |
| HLA and donor type | |
| HLA-matched related | 1819 (46) |
| Unrelated HLA-matched, confirmed by high-resolution typing | 1213 (31) |
| Unrelated HLA-matched, unconfirmed by high-resolution typing | 239 (6) |
| HLA-mismatched unrelated | 666 (17) |
| Graft source | |
| Bone marrow | 2179 (56) |
| Mobilized blood cells | 1739 (44) |
| Conditioning regimen | |
| Myeloablative with <1000 cGy total body irradiation | 1340 (34) |
| Myeloablative with ≥1000 cGy total body irradiation | 1887 (18) |
| Nonmyeloablative | 691 (18) |
| Prior grade 2-4 acute GVHD* | 2848 (73) |
Grades were not assigned for 23 recipients.